Oncotarget

Research Papers:

Circulating resistin levels and obesity-related cancer risk: A meta-analysis

Wei-Jing Gong, Wei Zheng, Ling Xiao, Li-Ming Tan, Jian Song, Xiang-Ping Li, Di Xiao, Jia-Jia Cui, Xi Li, Hong-Hao Zhou, Ji-Ye Yin and Zhao-Qian Liu _

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2016; 7:57694-57704. https://doi.org/10.18632/oncotarget.11034

Metrics: PDF 2261 views  |   HTML 2874 views  |   ?  


Abstract

Wei-Jing Gong1,2,3, Wei Zheng1,2, Ling Xiao1,2, Li-Ming Tan1,2, Jian Song4, Xiang-Ping Li5, Di Xiao1,2, Jia-Jia Cui1,2, Xi Li1,2, Hong-Hao Zhou1,2, Ji-Ye Yin1,2,3 and Zhao-Qian Liu1,2,3

1 Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, P. R. China

2 Institute of Clinical Pharmacology, Central South University, Hunan Key Laboratory of Pharmacogenetics, Changsha, P. R. China

3 Hunan Province Cooperation Innovation Center for Molecular Target New Drug Study, Hengyang, P. R. China

4 Department of Otolaryngology, Xiangya Hospital, Central South University, Changsha, P.R. China

5 Department of Pharmacy, Xiangya Hospital, Central South University, Changsha, P.R. China

Correspondence to:

Zhao-Qian Liu, email:

Ji-Ye Yin, email:

Keywords: circulating resistin levels, obesity-related cancer, meta-analysis

Received: March 26, 2016 Accepted: July 19, 2016 Published: August 04, 2016

Abstract

Resistin levels have been reported to be abnormal in obesity-related cancer patients with epidemiological studies yielding inconsistent results. Therefore, a meta-analysis was performed to assess the association between blood resistin levels and obesity-related cancer risk. A total of 13 studies were included for pooling ORs analysis. High resistin levels were found in cancer patients (OR= 1.20, 95% CI= 1.10-1.30). After excluding one study primarily contributing to between-study heterogeneity, the association between resistin levels and cancer risk was still significant (OR=1.18, 95% CI = 1.09-1.28). Stratification analysis found resistin levels were not associated with cancer risk in prospective studies. Meta-regression analysis identified factors such as geographic area, detection assay, or study design as confounders to between-study variance. The result of 18 studies of pooling measures on SMD analysis was that high resistin levels were associated with increased cancer risk (SMD = 0.94, 95% CI = 0.63-1.25), but not in the pooling SMD analysis of prospective studies. Except for the studies identified as major contributors to heterogeneity by Galbraith plot, resistin levels were still higher in cancer patients (SMD = 0.75, 95% CI = 0.63-0.87) in retrospective studies. Meta-regression analysis found factors, such as geographic area, BMI-match, size, and quality score, could account for 66.7% between-study variance in pooling SMD analysis of retrospective studies. Publication bias was not found in pooling ORs analysis. Our findings indicated high resistin levels were associated with increased obesity-related cancer risk. However, it may not be a predictor.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 11034